Mounjaro and Wegovy may need to be continued for life, new research suggests

Key Concepts

• GLP-1 Receptor Agonists (Weight Loss Jabs): Medications like Marjaro (semaglutide) used for weight loss, mimicking a natural hormone to regulate appetite and blood sugar.
• Weight Regain: The common phenomenon of regaining lost weight after discontinuing weight loss treatments.
• Lifelong Treatment: The potential necessity of continued medication for individuals with obesity due to underlying biological predispositions.
• Cost & Accessibility: The financial burden and limited NHS availability of weight loss jabs.
• Long-Term Effects: The currently limited understanding of the safety and efficacy of prolonged GLP-1 receptor agonist use.

The Financial and Physiological Challenges of Long-Term Weight Loss Medication

The report focuses on the growing dilemma faced by individuals using GLP-1 receptor agonists – commonly referred to as “weight loss jabs” – for obesity treatment, specifically addressing the issues of cost, weight regain, and the potential need for lifelong medication. The central case study revolves around Rosie, who has regained four stone (approximately 25.4 kg) in the four months since stopping her weight loss jab, and is struggling with the increased cost of resuming treatment, now potentially up to £300 per month. She highlights the financial strain, stating, “I’m just trying to figure out what to do. It’s difficult when all the price of everything has gone up so much as well.”

Prevalence and Discontinuation Rates

A recent survey reveals a significant uptake in the use of these jabs, with almost 1 in 10 British adults either currently using them or seriously considering their use. However, research indicates a high discontinuation rate, with approximately half of users stopping treatment within 12 months. The primary reasons cited for stopping are cost and experiencing side effects.

Weight Regain & Health Reversal

Crucially, the report details the speed at which weight is regained after stopping medication. On average, individuals regain all lost weight within one and a half years. Furthermore, the benefits to underlying health conditions diminish even faster, within just 1.4 years. This rapid reversal of health improvements underscores the complexity of obesity treatment.

The Need for Lifelong Support

Scientists at the University of Oxford emphasize the likelihood of needing long-term support for individuals predisposed to weight gain. As stated by a researcher, “Most people who are living with obesity, who have all that genetic and metabolic predisposition to gain weight, are going to need lifelong support of some kind. Whether that's lifelong medication or whether it's medication at intervals combined with some other treatments, we just don't yet know.” This perspective shifts the focus from a ‘cure’ to a chronic management approach. The report highlights a critical distinction: losing weight is a different process than keeping weight off.

Limited Long-Term Data & Biological Impact

A significant concern raised is the lack of comprehensive data on the long-term safety and effectiveness of GLP-1 receptor agonists. Unlike medications for conditions like high cholesterol or blood pressure, the effects of prolonged use are largely unknown. Scientists acknowledge they don’t fully understand why weight is regained four times faster after stopping the drugs compared to stopping a traditional diet. The report suggests this may be linked to a significant and abrupt change in the body’s underlying biology.

Individual Experiences & Resource Constraints

Rosie’s experience is visually documented through photographs charting her weight loss journey from over 19 stone to just over 11 stone. She currently rations her remaining Marjaro pen, using occasional doses to manage her appetite. Her situation exemplifies the struggle many face – balancing the desire to maintain weight loss with the financial realities of ongoing treatment. She currently has enough medication for “probably two more doses.”

Conclusion

The report paints a complex picture of weight loss medication, highlighting its potential benefits alongside significant challenges. The increasing cost, high discontinuation rates, rapid weight regain, and lack of long-term data necessitate a re-evaluation of how obesity is treated. The prevailing view is shifting towards the acceptance of lifelong management, but the financial and logistical hurdles, particularly for those unable to access treatment through the NHS, remain substantial. The core takeaway is that addressing obesity requires a sustained, potentially lifelong, approach, and further research is crucial to understand the long-term effects and optimize treatment strategies.